Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 2.63 0.00% 0.00
CTXR closed unchanged on Thursday, July 19, 2018, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical CTXR trend table...

Date Alert Name Type % Chg
Jul 19 50 DMA Support Bullish 0.00%
Jul 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jul 19 Calm After Storm Range Contraction 0.00%
Jul 19 NR7 Range Contraction 0.00%
Jul 19 Inside Day Range Contraction 0.00%
Jul 19 Wide Bands Range Expansion 0.00%
Jul 18 50 DMA Support Bullish 0.00%
Jul 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jul 18 Wide Bands Range Expansion 0.00%
Jul 18 Down 3 Days in a Row Weakness 0.00%

Older signals for CTXR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Is CTXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.49
52 Week Low 2.08
Average Volume 49,286
200-Day Moving Average 3.3874
50-Day Moving Average 2.5743
20-Day Moving Average 2.489
10-Day Moving Average 2.6505
Average True Range 0.2175
ADX 21.65
+DI 25.6875
-DI 21.3463
Chandelier Exit (Long, 3 ATRs ) 2.4975
Chandelier Exit (Short, 3 ATRs ) 2.7325
Upper Bollinger Band 2.9586
Lower Bollinger Band 2.0194
Percent B (%b) 0.65
BandWidth 37.73403
MACD Line 0.0405
MACD Signal Line 0.0097
MACD Histogram 0.0308
Fundamentals Value
Market Cap 21.7 Million
Num Shares 8.25 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -1.33
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.80
Resistance 3 (R3) 2.78 2.71 2.77
Resistance 2 (R2) 2.71 2.67 2.72 2.76
Resistance 1 (R1) 2.67 2.64 2.69 2.69 2.75
Pivot Point 2.60 2.60 2.61 2.61 2.60
Support 1 (S1) 2.56 2.56 2.58 2.58 2.51
Support 2 (S2) 2.49 2.53 2.50 2.50
Support 3 (S3) 2.45 2.49 2.49
Support 4 (S4) 2.47